N-terminal region of a group b streptococcus surface protein as a carrier for the capsular polysaccharide
The immunogenic complex using N-terminal regions of Group B Streptococcus surface proteins as carriers for capsular polysaccharides addresses the limitations of current vaccines by enhancing immunogenicity and broadening strain coverage, offering efficient and safe protection against GBS infections.
WO2026109640A1 Publication Date: 2026-05-28MINERVAX
8 Cites 0 Cited by
Patent Information
- Application Number
- PCT/EP2025/083650
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-11-20
- Filing Date
- 2025-11-20
- Publication Date
- 2026-05-28
AI Technical Summary
Technical Problem
Current vaccines for Group B Streptococcus (GBS) infections provide limited protection against a wide range of strains, particularly type III strains, and often require multiple components, which complicates production and safety.
Method used
An immunogenic complex comprising an N-terminal region of a Group B Streptococcus surface protein, such as Rib, AlpC, Alp2, or Alp3, combined with a capsular polysaccharide, where the N-terminal region acts as a carrier for the polysaccharide, enhancing immunogenicity and coverage against various strains.
Benefits of technology
The immunogenic complex elicits protective immunity against a broad spectrum of GBS strains, reducing the number of components needed and improving production efficiency and safety.
✦ Generated by Eureka AI based on patent content.
Abstract
An immunogenic complex comprising i) an amino acid sequence of an N-terminal region of a group B Streptococcus surface protein selected from the group consisting of: a first amino acid sequence having at least 98%, such as 99%, identity to SEQ ID NO: 16 and a length of 172 amino acids to 178 amino acids; a second amino acid sequence having at least 98%, such as 99%, identity to SEQ ID NO: 18 and a length of 167 amino acids to 173 amino acids; and a third amino acid sequence consisting of SEQ ID NO: 20; and ii) a capsular polysaccharide, is provided. An immunogenic product, a vaccine, and the immunogenic complex, the immunogenic product or the vaccine for use in a method of preventing or treating a group B Streptococcus infection, are also provided.
Need to check novelty before this filing date? Find Prior Art